Gene-associated methylation status of ST14 as a predictor of survival and hormone receptor positivity in breast Cancer

Journal article

Abstract Background Genomic profiles of specific gene sets have been established to guide personalized treatment and prognosis for patients with breast cancer (BC). However, epigenomic information has not yet been applied in a clinical setting. ST14 encodes matriptase, a proteinase that is widely expressed in BC with reported prognostic value. Methods In this present study, we evaluated the effect of ST14 DNA methylation (DNAm) on overall survival (OS) of patients with BC as a representative example to promote the use of the epigenome in clinical decisions. We analyzed publicly available genomic and epigenomic data from 1361 BC patients. Methylation was characterized by the β-value from CpG probes based on sequencing with the Illumina Human 450 K platform. Results A high mean DNAm (β > 0.6779) across 34 CpG probes for ST14, as the gene-associated methylation (GAM) pattern, was associated with a longer OS after adjusting age, stage, histology and molecular features in Cox model (p value < 0.001). A high GAM status was also associated with a higher XBP1 expression level and higher proportion of hormone-positive BC (p value < 0.001). Pathway analysis revealed that altered GAM was related to matrisome-associated pathway. Conclusions Here we show the potential role of ST14 DNAm in BC prognosis and warrant further study.

Authors: Dai, Y-H; Wang, Y-F; Shen, P-C; Lo, C-H; Yang, J-F

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: BioMed Central
• Journal: BMC Cancer
• Volume: 21
• Issue: 1
• Pages: 945-945
• Publication date: 2021-08-21
• DOI: 10.1186/s12885-021-08645-3
• EISSN: 1471-2407
• ISSN: 1471-2407
• Language: English
• Keywords: Breast cancer; Cancer research; Biology; Surgical oncology; dNaM; Gene expression; Methylation; Oncology; Genetics; Internal medicine; Epigenomics; Gene; Medicine; Cancer; CpG site; DNA methylation; Bioinformatics